Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN79,8279,940,18
Msft0,65
Nokia4,324,38150,93
IBM0,57
Daimler AG79,0279,040,70
PFE0,36
25.06.2021 1:38:09
Indexy online
AD Index online
select
AD Index online
 

  • 24.06.2021
Evotec OAI (EVTG.DE, Xetra)
Závěr k 24.6.2021 Změna (%) Změna (EUR) Objem obchodů (EUR)
37,29 1,89 0,69 14 168 180
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 25.06.2021
Popis společnosti
Obecné informace
Název společnostiEvotec SE
TickerEVT
Kmenové akcie:Ordinary Shares
RICEVTG.DE
ISINDE0005664809
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.03.2021 3 735
Akcie v oběhu k 31.05.2021 164 354 321
MěnaEUR
Kontaktní informace
UliceEssener Bogen 7
MěstoHAMBURG
PSČ22419
ZeměGermany
Kontatní osobaGabriele Hansen
Funkce kontaktní osobySenior Vice President - Corporate Communications Marketing and Investor Relations
Telefon4 940 560 810
Fax494056081222
Kontatní telefon494 056 081 255

Business Summary: Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2021, Evotec SErevenues increased 11% to EUR133.1M. Net income increasedfrom EUR17.1M to EUR52.7M. Revenues reflect EVT Executesegment increase of 14% to EUR104.9M, EVT Innovate segmentincrease of 21% to EUR28.2M. Basic Earnings per Shareexcluding Extraordinary Items increased from EUR0.11 toEUR0.32.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 25.06.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Supervisory BoardWolfgang Plischke6917.06.201417.06.2014
Chief Executive Officer, Member of the Management BoardWerner Lanthaler5206.03.2009
Independent Vice Chairman of the Supervisory BoardIris Loewfriedrich6019.06.201919.06.2019
Chief Financial Officer, Member of the Management BoardEnno Spillner5118.07.201618.07.2016
Chief Operating Officer, Member of the Management BoardCraig Johnstone5101.01.201901.01.2019
Chief Scientific Officer, Member of the Management BoardCord Dohrmann5701.09.201001.09.2010